Nanobiotix

Equities

NANO

FR0011341205

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:18 2024-04-26 am EDT			5-day change	1st Jan Change
5.45 ^EUR	+0.93%		+3.81%	-17.92%

Apr. 25	Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024
Apr. 24	Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Nanobiotix: targets achieved for NANORAY-312

January 30, 2024 at 01:17 am EST

Nanobiotix announces the achievement of operational milestones for NANORAY-312, an ongoing pivotal Phase III study evaluating the radioenhancer first-in-class potential of NBTXR3 in elderly patients with head and neck cancer.

This achievement entails a $20 million milestone payment from Janssen Pharmaceutica, a Johnson & Johnson subsidiary and strategic partner of the French biotech company under a worldwide licensing agreement.

Copyright (c) 2024 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Latest news about Nanobiotix

Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024	Apr. 25
Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Nanobiotix completes escalation portion of 2020-0123 study	Apr. 03	CF
Nanobiotix Completes Dose Escalation Segment of Phase 1 Study Targeting Non-Small Cell Lung Cancer	Apr. 02	MT
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommends Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation	Apr. 02	CI
Nanobiotix Gets $20 Million Milestone Payment in Phase 3 Trial for Potential Head, Neck Cancer Drug	Jan. 30	MT
Nanobiotix: targets achieved for NANORAY-312	Jan. 30	CF
Nanobiotix Gets $20 Million Milestone Payment from Janssen	Jan. 30	MT
Nanobiotix: transfer of NBTXR3 rights in Asia	Dec. 27	CF
Nanobiotix Partner Transfers Asian Commercialization Rights for Oncology Therapy to Johnson & Johnson Unit	Dec. 27	MT
LianBio Assigns Rights to Nanobiotix's Oncology Therapy in China, Other Asian Markets to Janssen Pharmaceutica	Dec. 26	MT
ADRs Advance, Argo Blockchain PLC Climbs 35.0%	Dec. 22	DJ
Valneva Shareholders OK One-tier Governance Model; New Chair Appointed	Dec. 21	MT
Nanobiotix: closing of remaining JJDC placement	Dec. 05	CF
Nanobiotix Closes Issuance of Additional Shares to Johnson & Johnson Innovation – JJDC	Dec. 05	MT
Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.	Dec. 03	CI
Johnson & Johnson Discloses Stake in Nanobiotix	Nov. 17	MT
Transcript : Nanobiotix S.A., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Nanobiotix Raises EUR50.9 Million via Global Follow-on Offering	Nov. 08	MT
But where have the bears gone?	Nov. 03
ADRs Advance; Trivago N.V. Climbs 86.6%	Nov. 02	DJ
Nanobiotix Prices $55 Million Share Sale in US, Europe; Paris Stock Closes Lower	Nov. 02	MT
The Fed doesn't want to raise rates (but is pretending to)	Nov. 02
Nanobiotix launches global offering	Nov. 02	CF

Chart Nanobiotix

Duration

Period

More charts

Company Profile

Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without increasing the dose received by the surrounding healthy tissue. NanoXray products are compatible with standard radiotherapy treatments and are intended to potentially treat a wide variety of cancers via multiple routes of administration. The company's resources are primarily devoted to the development of its lead product candidate: NBTXR3, which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Nanobiotix

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.45 EUR

Average target price

10.98 EUR

Spread / Average Target

+101.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NANOBIOTIX	-17.92%	274M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research